nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Albumin-like material in urine
|
Comper, Wayne D. |
|
|
66 |
S92 |
p. S65-S66 |
artikel |
2 |
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study
|
Ibsen, Hans |
|
|
66 |
S92 |
p. S56-S58 |
artikel |
3 |
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease
|
Mann, Johannes F.E. |
|
|
66 |
S92 |
p. S59-S62 |
artikel |
4 |
Albuminuria as a surrogate marker for drug development: A European Regulatory perspective
|
Calvo, Gonzalo |
|
|
66 |
S92 |
p. S126-S127 |
artikel |
5 |
Albuminuria: Marker or target in indigenous populations
|
Hoy, Wendy |
|
|
66 |
S92 |
p. S25-S31 |
artikel |
6 |
Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
|
De Zeeuw, Dick |
|
|
66 |
S92 |
p. S2-S6 |
artikel |
7 |
Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia–Pacific Rim
|
Weir, Matthew R. |
|
|
66 |
S92 |
p. S38-S39 |
artikel |
8 |
An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population
|
Verhave, Jacobien C. |
|
|
66 |
S92 |
p. S18-S21 |
artikel |
9 |
Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy
|
Jacobsen, Peter |
|
|
66 |
S92 |
p. S108-S110 |
artikel |
10 |
Cardiovascular risk in chronic kidney disease
|
Anavekar, Nagesh S. |
|
|
66 |
S92 |
p. S11-S15 |
artikel |
11 |
Demographic and epidemiologic transition in the developing world: Role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease
|
Correa-Rotter, Ricardo |
|
|
66 |
S92 |
p. S32-S37 |
artikel |
12 |
Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease
|
Mitch, William E. |
|
|
66 |
S92 |
p. S97-S98 |
artikel |
13 |
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension
|
Segura, Julian |
|
|
66 |
S92 |
p. S45-S49 |
artikel |
14 |
Framingham score and microalbuminuria: Combined future targets for primary prevention?
|
Asselbergs, Folkert W. |
|
|
66 |
S92 |
p. S111-S114 |
artikel |
15 |
Glomerular filtration of albumin: How small is the sieving coefficient?
|
Deen, William M. |
|
|
66 |
S92 |
p. S63-S64 |
artikel |
16 |
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria
|
Palmer, Andrew J. |
|
|
66 |
S92 |
p. S118-S120 |
artikel |
17 |
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial
|
Hunsicker, Lawrence G. |
|
|
66 |
S92 |
p. S99-S101 |
artikel |
18 |
Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease
|
Warnock, David G. |
|
|
66 |
S92 |
p. S121-S123 |
artikel |
19 |
Inclusion of albuminuria in hypertension and heart guidelines
|
Bakris, George |
|
|
66 |
S92 |
p. S124-S125 |
artikel |
20 |
Introduction
|
De Zeeuw, Dick |
|
|
66 |
S92 |
p. S1 |
artikel |
21 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy
|
Alexander, Charles M. |
|
|
66 |
S92 |
p. S115-S117 |
artikel |
22 |
Mechanism of albuminuria associated with cardiovascular disease and kidney disease
|
Russo, Leileata M. |
|
|
66 |
S92 |
p. S67-S68 |
artikel |
23 |
Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2
|
Mogensen, Carl Erik |
|
|
66 |
S92 |
p. S40-S41 |
artikel |
24 |
Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study
|
Stehouwer, Coen D.A. |
|
|
66 |
S92 |
p. S42-S44 |
artikel |
25 |
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria
|
Anavekar, Nagesh S. |
|
|
66 |
S92 |
p. S50-S55 |
artikel |
26 |
Prevalence of albuminuria in Australia: The AusDiab Kidney Study
|
Atkins, Robert C. |
|
|
66 |
S92 |
p. S22-S24 |
artikel |
27 |
Proteinuria and hypertensive nephrosclerosis in African Americans
|
Toto, Robert D. |
|
|
66 |
S92 |
p. S102-S104 |
artikel |
28 |
Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN)
|
Remuzzi, Giuseppe |
|
|
66 |
S92 |
p. S90-S96 |
artikel |
29 |
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes
|
Forbes, Josephine M. |
|
|
66 |
S92 |
p. S105-S107 |
artikel |
30 |
Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?
|
Gansevoort, Ron T. |
|
|
66 |
S92 |
p. S7-S10 |
artikel |
31 |
Which albumin should we measure?
|
Becker, Gavin J. |
|
|
66 |
S92 |
p. S16-S17 |
artikel |
32 |
Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC
|
Brinkman, Jacoline W. |
|
|
66 |
S92 |
p. S69-S75 |
artikel |
33 |
Why is proteinuria an ominous biomarker of progressive kidney disease?
|
Zandi-Nejad, Kambiz |
|
|
66 |
S92 |
p. S76-S89 |
artikel |